Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PAM | P19021 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16871129 | 0.83 | GSK3B (0.40) | BCHEALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL11073006 | 0.70 | BCHE (0.41) | BCHEALDH1A1SMN1; SMN2 | |
| SCHEMBL16871051 | 0.65 | ALDH1A1 (0.44) | MCHR1BCHEALDH1A1ALDH3A1RCE1 | |
| SCHEMBL19076255 | 0.65 | ALDH1A1 (0.53) | BCHEALDH1A1ALDH3A1RCE1HSD17B10 | |
| SCHEMBL28168110 | 0.63 | NOX1 (0.41) | BCHEPOLB | |
| SCHEMBL27893554 | 0.62 | GSK3B (0.41) | BCHEALDH1A1SMN1; SMN2 | |
| SCHEMBL28131846 | 0.61 | NOX1 (0.42) | BCHESMN1; SMN2 | |
| (Z)-1,2-Diphenylethene SCHEMBL27764636 | 0.60 | ALDH1A1 (0.70) | BCHEALDH1A1PAMSMN1; SMN2 | |
| SCHEMBL1158301 | 0.60 | PAM (0.68) | BCHEALDH1A1PAMSMN1; SMN2 | |
| SCHEMBL1158302 | 0.60 | PAM (0.68) | BCHEALDH1A1PAMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150183772-A1 | ALKYLATION OF AZOLES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183772-A1 | ALKYLATION OF AZOLES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183772-A1 | ALKYLATION OF AZOLES | AKR1C3, DCXR, AKR1C2 | MCHR1 2903/4885BCHE 4026/4885ALDH1A1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.